Distinct from conventional GBM, E-GBM frequently harbors BRAF V600E mutations, TERT promoter mutations, and CDKN2A/B homozygous deletions, correlating with aggressive clinical behavior, rapid recurrence, and dismal prognosis (13). Here, BRAF is linked to glioblastoma.